Ultimovacs ASA (OL:ULTI) — Stock Price
Ultimovacs ASA (OL:ULTI) is currently trading at Nkr14.40 NOK, up 0.00% today. Over the past 52 weeks, shares have ranged between Nkr14.40 and Nkr14.40. This page tracks Ultimovacs ASA's live share price on the OL exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see ULTI company net worth.
Ultimovacs ASA (ULTI) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Ultimovacs ASA's daily closing share price and trading volume on the OL exchange over the past year, giving a clear view of recent price momentum and liquidity.
Daily price history is not currently available for Ultimovacs ASA.
Ultimovacs ASA Income Statement — Revenue, Profit & Earnings by Year
Ultimovacs ASA's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | Nkr0.00 | Nkr0.00 | Nkr0.00 | Nkr0.00 | Nkr0.00 |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Research & Development | Nkr88.68 Million | Nkr123.83 Million | Nkr95.17 Million | Nkr96.73 Million | Nkr64.66 Million |
| SG&A | Nkr11.28 Million | Nkr6.48 Million | Nkr75.69 Million | Nkr61.92 Million | Nkr3.98 Million |
| Total Operating Expenses | Nkr151.26 Million | Nkr215.73 Million | Nkr183.63 Million | Nkr163.83 Million | Nkr124.15 Million |
| Operating Income | Nkr-151.26 Million | Nkr-215.73 Million | Nkr-183.63 Million | Nkr-163.83 Million | Nkr-124.15 Million |
| EBITDA | — | — | Nkr-180.98 Million | Nkr-161.69 Million | Nkr-117.59 Million |
| EBIT | — | — | — | Nkr-163.83 Million | Nkr-124.15 Million |
| Interest Expense | Nkr1.39 Million | Nkr3.14 Million | — | Nkr333.00K | Nkr240.00K |
| Income Before Tax | Nkr-212.71 Million | Nkr-189.24 Million | Nkr-167.79 Million | Nkr-164.72 Million | Nkr-120.55 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | Nkr-201.06 Million | Nkr-189.24 Million | Nkr-167.79 Million | Nkr-164.72 Million | Nkr-120.55 Million |
Ultimovacs ASA Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Ultimovacs ASA's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | Nkr115.86 Million | Nkr349.04 Million | Nkr509.67 Million | Nkr655.54 Million | Nkr529.72 Million |
| Total Current Assets | Nkr113.85 Million | Nkr272.12 Million | Nkr435.58 Million | Nkr582.25 Million | Nkr449.36 Million |
| Cash & Equivalents | — | — | Nkr1.82 Million | Nkr1.85 Million | Nkr1.83 Million |
| Short-term Investments | — | — | Nkr4.99 Million | Nkr5.31 Million | Nkr6.94 Million |
| Net Receivables | — | — | Nkr6.27 Million | Nkr6.45 Million | Nkr7.69 Million |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | Nkr5.66 Million | Nkr2.16 Million | Nkr4.01 Million |
| Goodwill | Nkr0.00 | Nkr11.65 Million | Nkr10.70 Million | Nkr11.03 Million | Nkr11.79 Million |
| Total Liabilities | Nkr33.19 Million | Nkr69.65 Million | Nkr60.32 Million | Nkr62.38 Million | Nkr41.34 Million |
| Total Current Liabilities | Nkr31.48 Million | Nkr56.11 Million | Nkr45.91 Million | Nkr50.90 Million | Nkr27.47 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | Nkr82.67 Million | Nkr279.39 Million | Nkr449.35 Million | Nkr593.15 Million | Nkr488.38 Million |
| Retained Earnings | Nkr-1.06 Billion | Nkr-861.35 Million | Nkr-672.11 Million | Nkr-504.32 Million | Nkr-339.60 Million |
Ultimovacs ASA Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Ultimovacs ASA generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | Nkr-163.40 Million | Nkr-189.83 Million | Nkr-167.69 Million | Nkr-125.83 Million | Nkr-108.22 Million |
| Capital Expenditures | Nkr17.00K | Nkr25.00K | Nkr195.00K | Nkr85.00K | Nkr282.00K |
| Free Cash Flow | Nkr-163.42 Million | Nkr-189.85 Million | Nkr-167.89 Million | Nkr-125.91 Million | Nkr-113.50 Million |
| Investing Cash Flow | — | — | Nkr8.69 Million | Nkr2.98 Million | Nkr-736.00K |
| Financing Cash Flow | — | — | Nkr3.58 Million | Nkr259.96 Million | Nkr151.02 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | Nkr4.34 Million | Nkr14.26 Million | Nkr20.39 Million | Nkr11.60 Million | Nkr6.78 Million |
| Depreciation | Nkr2.77 Million | Nkr2.77 Million | Nkr2.65 Million | Nkr2.70 Million | Nkr2.72 Million |
| Change in Cash | Nkr-157.09 Million | Nkr-177.64 Million | Nkr-148.86 Million | Nkr133.24 Million | Nkr41.32 Million |
Ultimovacs ASA Earnings History — EPS Actual vs. Analyst Estimates
Track Ultimovacs ASA's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 05, 2025 | — | — | — |
| Jan 31, 2025 | -3.13 | — | — |
| Nov 06, 2024 | -0.75 | — | — |
| Aug 21, 2024 | -1.30 | — | — |
| May 07, 2024 | -0.66 | — | — |
| Feb 14, 2024 | -1.63 | — | — |
| Nov 08, 2023 | -1.62 | — | — |
| Aug 22, 2023 | -1.26 | — | — |